A Study to Evaluate Safety and Tolerability of Olipudase Alfa in Pediatric and Adult Participants With Acid Sphingomyelinase Deficiency (ASMD) Who Completed the DFI12712 or the LTS13632 Study in France

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 18, 2021

Primary Completion Date

April 8, 2025

Study Completion Date

April 8, 2025

Conditions

Niemann-Pick Disease

Interventions

DRUG

Olipudase alfa

Pharmaceutical form:Powder for concentrate for solution for infusion-Route of administration:intravenous infusion

Trial Locations (2)

Investigational Site Number : 2500002, Bron

Investigational Site Number : 2500001, Paris